Stockwatch: Its about the data
This article was originally published in Scrip
Long-suffering investors in Switzerland's Addex received a welcome boost when the company reported positive phase IIa results for its mGluR5 negative allosteric modulator, dipraglurant for Parkinson’s Disease (PD) (scripintelligence.com, 22 March 2012). The Addex share price jumped over 80% on the announcement, reflecting the relief by many investors that the Addex platform for discovering allosteric modulators may come up with something after a few disappointments.
You may also be interested in...
If demand-side pressures on the life science sector were not enough, generic price erosion, debt repayment and extended restructurings are worsening the generic pharmaceutical investment proposition.
Depending on the therapeutic area, a fall in pharmaceutical sales was an obvious effect of the pandemic, although lower selling and marketing expenses and fewer non-COVID-19 infections were minor positives.
Roche’s full-year 2020 results suggested that it had seen better days. By contrast, the turnaround narrative at AstraZeneca suggested that its worst days were behind it.